We are live on ! Find out more
IDNA icon

iShares Genomics Immunology and Healthcare ETF

67 hedge funds and large institutions have $46.7M invested in iShares Genomics Immunology and Healthcare ETF in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.64% less ownership

Funds ownership: 30.34%27.7% (-2.6%)

8% less funds holding

Funds holding: 7367 (-6)

12% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 17

18% less capital invested

Capital invested by funds: $57.1M → $46.7M (-$10.4M)

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

Holders
67
Holders Change
-6
Holders Change %
-8.22%
% of All Funds
1.15%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
15
Reduced
17
Closed
14
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
TFS
76
TrustCore Financial Services
Tennessee
-$6K -205 Closed
EIP
77
Ellis Investment Partners
Pennsylvania
-$4.04K -131 Closed
Qube Research & Technologies (QRT)
78
Qube Research & Technologies (QRT)
United Kingdom
-$2K -56 Closed

IDNA Hedge Fund Activity: Q3 2022 in Review

67 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q3 2022, worth a combined $46.7M — down 18% from $57.1M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of IDNA and 8 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 15 added.

The largest buyer was Morgan Stanley, adding an estimated $1.76M. The largest seller was Jane Street, cutting an estimated $2.37M.

  • 67 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q3 2022, down from 73 in Q2 2022.
  • Funds reported $46.7M of iShares Genomics Immunology and Healthcare ETF stock for Q3 2022, down 18% quarter-over-quarter.
  • 8 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q3 2022 and 14 closed out, a net change of -6 holders.
  • The largest iShares Genomics Immunology and Healthcare ETF buyer in Q3 2022 was Morgan Stanley, an estimated $1.76M added.
  • The largest iShares Genomics Immunology and Healthcare ETF seller in Q3 2022 was Jane Street, an estimated $2.37M sold.

Based on aggregated 13F filings for Q3 2022.